CONFLUENCE LIFE SCIENCES INC / ACLARIS THERAPEUTICS INC / Acquisition / Private / £15m

Synopsis

Sale of Confluence Life Sciences, a biotechnology company focused on the kinase inhibitors to treat inflammatory and immunological disorders and cancer, to Aclaris Therapeutics.

Principals

target

Confluence Life Sciences

bidder

Aclaris Therapeutics

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (1)

luke bergstrom

Partner at Latham & Watkins

Lawyer

target

Deals

£ 57.01 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy